ADC Therapeutics SA expected to post a loss of 63 cents a share - Earnings Preview

ADC Therapeutics SA

03/11/2023 19:25

* ADC Therapeutics SA  ADCT.N   ADCT.K  is expected to show
a fall
in quarterly revenue when it reports  results on November 7. 
    * The Epalinges Vaud-based  company is expected to report  a
80.1% decrease in revenue to $15.158 million from $76.32 million
a year ago, according to the mean estimate from 5 analysts,
based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for ADC Therapeutics SA
is
for a loss of 63 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ADC
Therapeutics
SA is $9.5​, above​ its last closing price of $0.70. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.35       -0.46      -0.58     Missed  -26.9
 Mar. 31 2023  -0.76       -0.67      -0.74     Missed  -10.4
 Dec. 31 2022  -0.21       -0.29      -0.30     Missed  -4.6​
 Sep. 30 2022  -0.30       -0.35      -0.65     Missed  -84.2
 ​​Jun.        -0.92       -0.91      -0.84     Beat    8.1
 30 2022                                                
 Mar. 31 2022  -0.69       -0.70      -0.22     Beat    68.4​
 Dec. 31 2021  -0.86       -0.86      -0.45     Beat    47.5
 Sep. 30 2021  -0.96       -0.92      -0.93     Missed  -1.4
 This summary was machine generated November 3 at 19:25 GMT.  All
figures in US dollars  unless otherwise stated